A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.

Principal Investigator

  • Gordon Li, MD

Stanford Investigator(s)

  • Seema Nagpal, MD


Primary Contact:
Vani Jain
(650) 723-1005